share_log

Johnson & Johnson | 8-K: Johnson & Johnson Reports Q1 2024 Results and Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%

Johnson & Johnson | 8-K: Johnson & Johnson Reports Q1 2024 Results and Announces 62nd Consecutive Year of Dividend Increase; Raises Quarterly Dividend by 4.2%

强生 | 8-K：强生公布2024年第一季度业绩并宣布连续62年增加股息；将季度股息提高4.2%
美股sec公告 ·  04/16 07:10
Moomoo AI 已提取核心信息
On April 16, 2024, Johnson & Johnson reported its financial results for the first quarter ended March 31, 2024. The company announced a reported sales growth of 2.3% reaching $21.4 billion, with an operational growth of 3.9% and an adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, the adjusted operational growth was 7.7%. Earnings per share (EPS) increased to $2.20, and adjusted EPS rose to $2.71, marking a 12.4% increase. Additionally, Johnson & Johnson's Board of Directors declared a 4.2% increase in the quarterly dividend rate, from $1.19 to $1.24 per share, continuing a 62-year streak of consecutive dividend increases. The next dividend is scheduled to be paid on June 4, 2024, to shareholders of record as of May 21, 2024. The company also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The report highlighted the performance of key products and segments, including Innovative Medicine and MedTech, and noted several regulatory approvals and product launches. Johnson & Johnson emphasized its commitment to healthcare innovation and its position in the industry.
On April 16, 2024, Johnson & Johnson reported its financial results for the first quarter ended March 31, 2024. The company announced a reported sales growth of 2.3% reaching $21.4 billion, with an operational growth of 3.9% and an adjusted operational growth of 4.0%. Excluding the COVID-19 vaccine, the adjusted operational growth was 7.7%. Earnings per share (EPS) increased to $2.20, and adjusted EPS rose to $2.71, marking a 12.4% increase. Additionally, Johnson & Johnson's Board of Directors declared a 4.2% increase in the quarterly dividend rate, from $1.19 to $1.24 per share, continuing a 62-year streak of consecutive dividend increases. The next dividend is scheduled to be paid on June 4, 2024, to shareholders of record as of May 21, 2024. The company also raised its full-year 2024 operational sales and adjusted operational EPS guidance. The report highlighted the performance of key products and segments, including Innovative Medicine and MedTech, and noted several regulatory approvals and product launches. Johnson & Johnson emphasized its commitment to healthcare innovation and its position in the industry.
2024年4月16日，强生公司公布了截至2024年3月31日的第一季度财务业绩。该公司宣布，销售额增长2.3％，达到214亿美元，运营增长3.9％，调整后的运营增长4.0％。不包括 COVID-19 疫苗，调整后的业务增长为7.7％。每股收益（EPS）增至2.20美元，调整后的每股收益升至2.71美元，增长12.4％。此外，强生董事会宣布将季度股息率提高4.2％，从每股1.19美元提高至1.24美元，延续了62年来股息连续增长的势头。下一次股息计划于2024年6月4日支付给截至2024年5月21日的登记股东。该公司还提高了2024年全年营业销售额并调整了运营每股收益预期。该报告重点介绍了包括创新医学和医疗技术在内的关键产品和细分市场的表现，并指出了几项监管批准和产品发布。强生公司强调了其对医疗创新的承诺及其在行业中的地位。
2024年4月16日，强生公司公布了截至2024年3月31日的第一季度财务业绩。该公司宣布，销售额增长2.3％，达到214亿美元，运营增长3.9％，调整后的运营增长4.0％。不包括 COVID-19 疫苗，调整后的业务增长为7.7％。每股收益（EPS）增至2.20美元，调整后的每股收益升至2.71美元，增长12.4％。此外，强生董事会宣布将季度股息率提高4.2％，从每股1.19美元提高至1.24美元，延续了62年来股息连续增长的势头。下一次股息计划于2024年6月4日支付给截至2024年5月21日的登记股东。该公司还提高了2024年全年营业销售额并调整了运营每股收益预期。该报告重点介绍了包括创新医学和医疗技术在内的关键产品和细分市场的表现，并指出了几项监管批准和产品发布。强生公司强调了其对医疗创新的承诺及其在行业中的地位。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息